How do you manage patients with BRAF V600E-mutated metastatic melanoma who have a mixed radiographic response after several months of therapy with dabrafenib/trametinib?   

Does the site of progression or response matter?  What if there is progression in the lungs but response in lymphadenopathy, for example?  

Answer from: Medical Oncologist at Academic Institution